ATE146819T1 - Therapeutisches anti-hiv oligonukleotid und arzneimittel - Google Patents

Therapeutisches anti-hiv oligonukleotid und arzneimittel

Info

Publication number
ATE146819T1
ATE146819T1 AT93924289T AT93924289T ATE146819T1 AT E146819 T1 ATE146819 T1 AT E146819T1 AT 93924289 T AT93924289 T AT 93924289T AT 93924289 T AT93924289 T AT 93924289T AT E146819 T1 ATE146819 T1 AT E146819T1
Authority
AT
Austria
Prior art keywords
hiv
oligonucleotides
medicinal product
therapeutic anti
disclosed
Prior art date
Application number
AT93924289T
Other languages
English (en)
Inventor
Sudhir Agrawal
Jin Yan Tang
Original Assignee
Hybridon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybridon Inc filed Critical Hybridon Inc
Application granted granted Critical
Publication of ATE146819T1 publication Critical patent/ATE146819T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7125Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • AIDS & HIV (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
AT93924289T 1992-10-05 1993-10-04 Therapeutisches anti-hiv oligonukleotid und arzneimittel ATE146819T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95813592A 1992-10-05 1992-10-05

Publications (1)

Publication Number Publication Date
ATE146819T1 true ATE146819T1 (de) 1997-01-15

Family

ID=25500631

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93924289T ATE146819T1 (de) 1992-10-05 1993-10-04 Therapeutisches anti-hiv oligonukleotid und arzneimittel

Country Status (19)

Country Link
US (1) US5684147A (de)
EP (1) EP0664833B1 (de)
JP (1) JPH08504570A (de)
KR (1) KR950704482A (de)
AT (1) ATE146819T1 (de)
AU (1) AU678415B2 (de)
BR (1) BR9307191A (de)
CA (1) CA2146364A1 (de)
CZ (1) CZ85495A3 (de)
DE (1) DE69306969T2 (de)
DK (1) DK0664833T3 (de)
ES (1) ES2096343T3 (de)
FI (1) FI951600L (de)
GR (1) GR3022315T3 (de)
HU (1) HUT72400A (de)
NO (1) NO951307L (de)
NZ (1) NZ257434A (de)
PL (1) PL308261A1 (de)
WO (1) WO1994008004A1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US5733781A (en) * 1994-07-19 1998-03-31 Gen-Probe Incorporated Oligonucleotides and methods for inhibiting propagation of human immunodeficiency virus
US6776986B1 (en) 1996-06-06 2004-08-17 Novartis Ag Inhibition of HIV-1 replication by antisense RNA expression
RU2136752C1 (ru) * 1997-05-22 1999-09-10 Государственный научный центр вирусологии и биотехнологии "Вектор" Способ ингибирования репродукции вируса иммунодефицита человека
EP1584681A3 (de) * 1997-07-10 2005-11-09 GeneSense Technologies Inc. Antisense oligonukleotid-sequenzen als inhibitoren für mikroorganismen
US6610539B1 (en) * 1997-07-10 2003-08-26 Genesense Technologies, Inc. Antisense oligonucleotide sequences as inhibitors of microorganisms
ES2255732T3 (es) 1997-08-19 2006-07-01 Idera Pharmaceuticals, Inc. Oligonucleotidos especificos de vih y procedimientos para su utilizacion.
SI1077722T1 (sl) 1998-05-22 2007-02-28 Ottawa Health Research Inst Metode in produkti za induciranje sluznicne imunosti
NZ512244A (en) 1998-11-12 2003-12-19 Invitrogen Corp Polycationic transfection reagents for introducing anions into a cell
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
JP4824236B2 (ja) * 1999-07-09 2011-11-30 ジェン−プローブ・インコーポレーテッド 核酸増幅によるhiv−1の検出
WO2001046448A1 (en) * 1999-12-23 2001-06-28 The Board Of Regents Of The University Of Texas System Inhibition of cellular proteases
AU2001227889A1 (en) * 2000-01-14 2001-07-24 The United States of America, represented by The Secretary, Department of Health & Human Services Oligodeoxynucleotide and its use to induce an immune response
US6582920B2 (en) 2000-09-01 2003-06-24 Gen-Probe Incorporated Amplification of HIV-1 RT sequences for detection of sequences associated with drug-resistance mutations
JP2002125687A (ja) * 2000-10-30 2002-05-08 Tosoh Corp Hiv−1検出のためのオリゴヌクレオチドおよび検出法
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
WO2003020884A2 (en) 2001-08-14 2003-03-13 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Method for rapid generation of mature dendritic cells
ATE411054T1 (de) 2001-08-17 2008-10-15 Coley Pharm Gmbh Kombinations-motif-immunstimulierende oligonukleotide mit verbesserter wirkung
WO2003054161A2 (en) 2001-12-20 2003-07-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
US8263091B2 (en) 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
CN1753687A (zh) 2002-10-29 2006-03-29 科勒制药集团股份有限公司 Cpg寡核苷酸在治疗丙型肝炎病毒感染中的应用
CA2502015A1 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5' cpg nucleic acids and methods of use
EP1627563A1 (de) 2004-08-10 2006-02-22 Academisch Medisch Centrum bij de Universiteit van Amsterdam Verfahren und Mittel zur Herstellung einer stabilisierten Zelle
EP1647595A1 (de) * 2004-10-15 2006-04-19 Academisch Medisch Centrum bij de Universiteit van Amsterdam Nukleinsäuren gegen Viren, insbesondere gegen HIV
US8399423B2 (en) * 2005-10-12 2013-03-19 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
USRE49583E1 (en) 2005-11-17 2023-07-18 Tet Systems Gmbh & Co. Kg Inducible expression systems
ATE512228T1 (de) 2005-11-17 2011-06-15 Tet Systems Gmbh & Co Kg Induzierbare expressionssysteme
US9005974B2 (en) 2005-12-09 2015-04-14 Academish Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
NZ592159A (en) 2005-12-09 2012-12-21 Amc Amsterdam Means and methods for influencing the stability of antibody producing cells
US9273118B2 (en) 2009-07-15 2016-03-01 Aimm Therapeutics B.V. Means and methods for producing high affinity antibodies
AU2011230619C1 (en) 2010-03-25 2016-06-23 Oregon Health & Science University CMV glycoproteins and recombinant vectors
CN103429615B (zh) 2010-12-02 2018-03-16 埃姆医疗有限公司 用于生产高亲和力抗体的方式和方法
HUE037408T2 (hu) 2011-06-10 2018-08-28 Univ Oregon Health & Science CMV glikoproteinek és rekombináns vektorok
CA2789539A1 (en) 2011-09-12 2013-03-12 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
CA2958402C (en) * 2013-08-26 2021-02-02 The Royal Institution For The Advancement Of Learning / Mcgill University Antisense-based small rna agents targeting the gag open reading frame of hiv-1 rna
EP2848937A1 (de) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Verfahren zur Identifizierung neuartiger HIV-1-Immunogene
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
CA2938193C (en) 2014-01-31 2023-05-02 Aimm Therapeutics B.V. Means and methods for producing stable antibodies
EP3169310A1 (de) 2014-07-15 2017-05-24 Life Technologies Corporation Zusammensetzungen mit lipidaggregaten und verfahren zur effizienten bereitstellung von molekülen an zellen
EP3069730A3 (de) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0331939B1 (de) * 1988-02-16 2001-11-14 Greatbatch Gen-Aid, Ltd Modifizierte Zellen mit Resistenz gegen Retroviralinfektionen
JPH04501052A (ja) * 1988-02-26 1992-02-27 ザ・ウスター・フアウンデーシヨン・フオー・バイオメデイカル・リサーチ 外来性オリゴヌクレオチドによるhtlv―3の抑制

Also Published As

Publication number Publication date
AU678415B2 (en) 1997-05-29
HU9500995D0 (en) 1995-06-28
EP0664833B1 (de) 1996-12-27
KR950704482A (ko) 1995-11-20
CA2146364A1 (en) 1994-04-14
FI951600A0 (fi) 1995-04-04
ES2096343T3 (es) 1997-03-01
US5684147A (en) 1997-11-04
FI951600A7 (fi) 1995-05-10
BR9307191A (pt) 1999-03-30
WO1994008004A1 (en) 1994-04-14
NO951307L (no) 1995-06-01
EP0664833A1 (de) 1995-08-02
DE69306969T2 (de) 1997-05-07
NO951307D0 (no) 1995-04-04
GR3022315T3 (en) 1997-04-30
NZ257434A (en) 1997-01-29
AU5402894A (en) 1994-04-26
DK0664833T3 (da) 1997-04-14
JPH08504570A (ja) 1996-05-21
CZ85495A3 (en) 1996-03-13
HUT72400A (en) 1996-04-29
DE69306969D1 (de) 1997-02-06
FI951600L (fi) 1995-05-10
PL308261A1 (en) 1995-07-24

Similar Documents

Publication Publication Date Title
ATE146819T1 (de) Therapeutisches anti-hiv oligonukleotid und arzneimittel
AU8771398A (en) Novel hiv-specific synthetic oligonucleotides and methods of their use
WO1995000638A3 (en) Antisense oligonucleotides and therapeutic use thereof in human immunodeficiency virus infection
WO1994024144A3 (en) Enhanced triple-helix and double-helix formation with oligomers containing modified purines
ATE181960T1 (de) Gegensinnige hemmer des humanen immunmangel virus (hiv)
HU9403788D0 (en) Self-stabilized oligonucleotides as therapeutic agents
DE69330372D1 (de) ZUSAMMENSETZUNGEN UND VERFAHREN FüR DIE BEHANDLUNG VON MIT HEPATITIS C VIREN ASSOZIIERTEN KRANKHEITEN
ATE138384T1 (de) Olionukleotidalkylphosphonate und - phosphonothioate
DE68925278D1 (de) Hemmung von htlv-iii durch exogene oligonukleotide
PL319512A1 (en) Viral material and nucleotidic fragments associated with sclerosis multiplex or diagnostic, prophylactic and therapeutic purposes
Degols et al. Poly (L-lysine)-conjugated oligonucleotides promote sequence-specific inhibition of acute HIV-1 infection
KR960704034A (ko) 단백질 생산, 세포 증식 및(또는) 전염병 병원균의 증식에 대한 올리고뉴클레오티드 저해의 향상법(Enhancement of Oligonucleotide Inhibition of Protein Production, Cell Proliferation, and/or Multiplication of Infectious Disease Pathogens)
ATE395078T1 (de) Impfstoff zur vorbeugung bzw. behandlung der hepatitis c
AP1674A (en) The genome of the HIV-1 inter-subtype (C/B') and use thereof.
ES2112062T3 (es) Oligonucleotidos con actividad anti-citomegalovirus.
AU3881095A (en) Double-stranded oligonucleotide and carcinostatic agent containing the same as active ingredient
KR960000914A (ko) 이소프레닐 단백질 트랜스퍼라아제의 발현을 억제하는 올리고뉴클레오티드
TH23381A (th) โอลิโกนิวคลีโอไทด์สำหรับยับยั้งการแสดงลักษณะของไอโซพรีนิลโปรตีนทรานสเฟอเรส
Egan et al. Abasic Oligodeoxyribonucleoside Phosphorothioates as Inhibitors of the Human Immunodeficiency Virus-1 (HIV-1) Phosphorothioate Inhibition of HIV-1 Reverse Transcriptase and Interactions with Syrian Hampster Fibroblast (V79) Cells
WO2001079487A3 (de) Polydesoxyribonukleotide zur hemmung der icam-1-genexpression
ATE480560T1 (de) Zusammensetzung zur behandlung von periodontalen erkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee